---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075014"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:51:55.409825+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025

## Summary
- Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.
- LYMPHIR commercial launch planned for Q4 2025; launch supplies and distribution agreements in place.
- Raised $12.5M gross from parent equity offerings in Q3; Citius Oncology raised additional $9M in July 2025.
- On July 17, 2025, closed public offering with net proceeds of approximately $7.4M.
- Cash and cash equivalents were $112 as of June 30, 2025, subsequently improved by July financings.

## SEC filing metadata
- accession: 0001213900-25-075014
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/0001213900-25-075014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/ea0252884-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075014
- JSON: https://secwatch.observer/filing/0001213900-25-075014.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.